That's what I was hoping, that we would take a more responsible approach and wait for data. At this time, what they are seeking to do is diversify their portfolio of the types of vaccines available. I know there are a lot in the pipeline still. One of the miracles of the mRNA vaccines was based on the fact that you can just pump them out super fast, and that gave them an advantage so they could be a good filler. But at this point in time, if they were so good at coming up with new vaccines, then you would have thought that they would have already developed a variant-specific one, because right now, omicron is spreading because these vaccines don't show. It's an immune escape variant.
I think requiring more data and seeing whether or not it makes sense to actually vaccinate people who have already had omicron and recovered, and see what the benefit of that is, makes sense to me at this time.